Therapy Areas: Infectious Diseases
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
31 January 2024 -

Canadian life science company Ondine Biomedical Inc (LON: OBI), a specialist in photodisinfection therapies, announced on Wednesday that it has presented research at the SPIE Photonics West conference, demonstrating the efficacy of its Steriwave Nasal Photodisinfection System. The study revealed a significant immediate reduction (99.9+% ~3 log10) in viable bacterial cells and species in nasal swab samples, sustained for at least 24 hours. Importantly, the nasal microbiome rebounded to its original state within a week, supporting Steriwave as an efficient and non-selective method for nasal decolonisation.

Compared to antibiotics, Steriwave demonstrated a reduced likelihood of altering the native microbiota for an extended period. In contrast, antibiotics, like mupirocin, have shown long-term effects on microbiota diversity, potentially increasing the risk of infection. Ondine's technology, which uses light-activated antimicrobial photosensitizers, offers a more favorable profile by minimizing the risk of prolonged microbiome disruption.

Presented by Ondine's Director of Research and Development, Dr Caetano Sabino, the study involved 35 healthy volunteers and addressed the importance of minimizing microbiome disruption for immune function.

The SPIE Photonics West conference is a key event for optic and photonic technologies, attracting global researchers, innovators, engineers and business leaders.

Ondine Biomedical has a CE mark in Europe and the UK for its nasal photodisinfection system, named Steriwave. In the US, Steriwave has received Qualified Infectious Disease Product designation and Fast Track status from the FDA, currently undergoing clinical trials for regulatory approval. Beyond nasal photodisinfection, Ondine is developing therapies for various medical indications, including chronic sinusitis, ventilator-associated pneumonia, burns and more. The company's patented technology uses light-activated antimicrobials to destroy pathogens, providing a non-resistant alternative to antibiotics for nasal decolonisation.